Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab: RESULTS from the NORDIC VII Study

BACKGROUND: We aim to test the hypothesis that high plasma YKL-40 is associated with short progression-free survival (PFS) and overall survival (OS) in patients with metastatic colorectal cancer (mCRC) treated with first-line oxaliplatin and 5-flourouracil with or without cetuximab. PATIENTS AND MET...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Tarpgaard, Line S., Guren, Tormod K., Glimelius, Bengt, Christensen, Ib J., Pfeiffer, Per, Kure, Elin H., Sorbye, Halfdan, Ikdahl, Tone, Yilmaz, Mette, Johansen, Julia S., Tveit, Kjell Magne
פורמט: Artigo
שפה:Inglês
יצא לאור: Public Library of Science 2014
נושאים:
Research Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3912025/
https://ncbi.nlm.nih.gov/pubmed/24498368
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0087746
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים